Document text
Principal Investigator: STEVEN GREGORY REED
Organization: HDT BIO CORPORATION
Fiscal Year: 2024
Award: $543,301
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY/ABSTRACT
Our team - in collaboration with other vaccine developers - has been actively involved in tuberculosis (TB)
vaccine discovery for the past three decades and led the team that developed the M72 vaccine that has provided
proof of concept for effective subunit TB vaccines. Obstacles limiting commercial deployment of M72 include
limited efficacy (~50% prevention of disease) and cost of goods for large-scale production. With these
considerations in mind, our group developed a second-generation subunit vaccine, ID93, which consists of four
protein antigens (M72 has two) formulated with a synthetic TLR4 targeted adjuvant formulation, as opposed to
the natural product-based adjuvant contained in the M72 vaccine. ID93 has progressed to Phase 2 human clinical
trials, with promising results and is currently in further development. Human immune responses measured
against the ID93 components have been instructive and have allowed further antigen prioritization with a goal of
complementing the antigens of M72.
We have concurrently developed a new RNA vaccine platform - now in clinical development as a COVID-19
vaccine which may be approved in India in summer 2021 - and that induced potent cellular immunity and can be
scaled in a cost-effective manner. Using a select panel of antigens, we will apply our RNA technology for inducing
effective systemic and mucosal immune responses in mice and non-human primates. In addition, each of our
RNA based adjuvants, TLR3 and RIG-I agonists, both being effective inducers of both innate and adaptive
immune responses adds an innovative aspect.
In this proposal, our innovation comes from three main areas of emphasis: First is optimization of the RNA
vaccine technology by using new replicons and delivery systems. Second is applying RNA vaccination with
subunit protein/adjuvant boosting, using adjuvants of known efficacy (TLR4 agonists) in comparison with novel
adjuvants that signal through the TLR-3 or RIG-I pathways. Neither of these have been exploited extensively for
infectious disease vaccines - particularly in the area of mucosal immunity. The third area comes from innovation
in manufacturing and supply: We have novel processes for the production of TBRNA that were transferred to
India (Gennova) and Brazil (CIMATEC). Gennova has already produced 1 million doses, with a target of 100
million by year-end, and has completed Phase 1 and 2 clinical trials in India. Similarly, we have acquired large-
scale access to our adjuvant molecules (TLR4, TLR3, RIG-I), all synthetic, thus avoiding the intellectual property
roadblock encountered with M72.
Terms: <2019-nCoV vaccine><Address><Adjuvant><Aerosols><Agonist><Alpha Virus><Animals><Antigens><Area><Brazil><Businesses><COVID-19 vaccine><Cell Communication and Signaling><Cell Mediated Immunology><Cell Signaling><Cell-Mediated Immunity><Cellular Immunity><Clinical><Clinical Trials><Collaborations><Combination Vaccines><Combined Vaccines><Communicable Diseases><Coupled><Development><Dose><Early-Stage Clinical Trials><Formulation><Generations><Goals><Group A Arboviruses><Homolog of Drosophila TOLL><Human><Immune response><Immunization><Immunological response><India><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Innate Immune Response><Intellectual Property><Intracellular Communication and Signaling><Intramuscular><Kinetics><Lipids><Lung><Lung Respiratory System><M tb><M tuberculosis><M tuberculosis antigen><M tuberculosis infection><M. tb><M. tb infection><M. tuberculosis><M. tuberculosis antigen><M. tuberculosis infection><M.tb antigen><M.tb infection><M.tuberculosis infection><MTB infection><MTB vaccine><Measures><Mice><Mice Mammals><Mind><Modern Man><Mtb antigen><Mucosa><Mucosal Immune Responses><Mucosal Immunity><Mucosal Tissue><Mucous Membrane><Murine><Mus><Mycobacterium tuberculosis><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis antigens><Mycobacterium tuberculosis infection><Natural Products><Non-Polyadenylated RNA><Pathway interactions><Phase><Phase 1 Clinical Trials><Phase 2 Clinical Trials><Phase I Clinical Trials><Phase II Clinical Trials><Process><Production><Protein Subunits><Proteins><RNA><RNA Gene Products><RNA immunization><RNA replication><RNA vaccination><RNA vaccine><RNA-based vaccine><Recombinant Proteins><Regimen><Replication Unit><Replicon><Ribonucleic Acid><Risk><Route><SARS-CoV-2 vaccine><SARS-coronavirus-2 vaccine><Safety><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe acute respiratory syndrome coronavirus 2 vaccine><Signal Transduction><Signal Transduction Systems><Signaling><Subunit Vaccines><System><T-Cells><T-Lymphocyte><TB immunity><TB infection><TB vaccine><TLR3><TLR3 gene><TLR4><TLR4 gene><Technology><Testing><Toll Homologue><Toll-Like Receptor 3><Tuberculosis><Tuberculosis Vaccines><Vaccine for TB><Vaccine for Tuberculosis><Vaccines><adaptive immune response><anti-TB vaccine><biological signal transduction><clinical development><clinical relevance><clinically relevant><coronavirus disease 2019 vaccine><coronavirus disease-19 vaccine><cost><cost effective><deliver vaccines><deploy vaccines><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><discover vaccines><disease prevention><disorder prevention><disseminated TB><disseminated tuberculosis><distribute vaccines><full scale manufacturing><host response><immune system response><immunity against M. tuberculosis><immunity against Mtb><immunity against Mycobacterium tuberculosis><immunity against TB><immunity against tuberculosis><immunity in tuberculosis><immunity to TB><immunity to tuberculosis><immunization strategy><immunogen><immunogenicity><immunoresponse><improved><in vivo><infection due to Mycobacterium tuberculosis><innovate><innovation><innovative><large scale manufacturing><large scale production><mRNA immunization><mRNA vaccination><mRNA vaccine><mRNA-based vaccine><manufacture><mass production><mtb><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nano particle><nano-sized particle><nanoparticle><nanosized particle><naturally occurring product><non-human primate><nonhuman primate><novel><pathway><phase I protocol><phase II protocol><prevent><preventing><pulmonary><response><success><thymus derived lymphocyte><toll-like receptor 4><tuberculosis immunity><tuberculosis infection><tuberculous spondyloarthropathy><vaccination strategy><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against M. tuberculosis><vaccine against Mtb><vaccine against Mycobacterium tuberculosis><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine against TB><vaccine against tuberculosis><vaccine candidate><vaccine candidates against SARS-CoV-2><vaccine candidates against tuberculosis><vaccine delivery><vaccine deployment><vaccine development><vaccine discovery><vaccine distribution><vaccine for novel coronavirus><vaccine platform><vaccine roll-out><vaccine rollout><vaccines preventing COVID><vaccines to prevent COVID>